This story has been updated to clarify that Asuragen is offering a service, and not a diagnostic assay.
 
Looking to attract researchers involved in biomarker discovery using formalin-fixed, paraffin-embedded sample material, Asuragen next month will roll out a service that it claims can mitigate the factors that often lead scientists not to fully trust data derived from FFPE sample experiments.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.